Đang chuẩn bị liên kết để tải về tài liệu:
Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
The prognosis of patients with gastrointestinal stromal tumor (GIST) after the failure of standard therapies is poor with supportive care alone. Guidelines recommend clinical trials, and patients with good performance status following standard therapies are often eligible for phase I clinical trials of investigational agents; however, there are no detailed reports on the clinical outcomes of GIST patients enrolled in these trials. |